ES2717446T3 - Péptidos derivados de ERK y usos de los mismos - Google Patents
Péptidos derivados de ERK y usos de los mismos Download PDFInfo
- Publication number
- ES2717446T3 ES2717446T3 ES14846055T ES14846055T ES2717446T3 ES 2717446 T3 ES2717446 T3 ES 2717446T3 ES 14846055 T ES14846055 T ES 14846055T ES 14846055 T ES14846055 T ES 14846055T ES 2717446 T3 ES2717446 T3 ES 2717446T3
- Authority
- ES
- Spain
- Prior art keywords
- erk
- peptides derived
- peptides
- derived
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/11024—Mitogen-activated protein kinase (2.7.11.24), i.e. MAPK or MAPK2 or c-Jun N-terminal kinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361878633P | 2013-09-17 | 2013-09-17 | |
| PCT/IL2014/050822 WO2015040609A1 (en) | 2013-09-17 | 2014-09-15 | Erk-derived peptides and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2717446T3 true ES2717446T3 (es) | 2019-06-21 |
Family
ID=52688321
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14846055T Active ES2717446T3 (es) | 2013-09-17 | 2014-09-15 | Péptidos derivados de ERK y usos de los mismos |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US9695402B2 (es) |
| EP (1) | EP3046929B1 (es) |
| ES (1) | ES2717446T3 (es) |
| WO (1) | WO2015040609A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2662036T3 (es) | 2007-02-28 | 2018-04-05 | Yeda Research And Development Company Limited | Secuencias que se dirigen al núcleo |
| US9695402B2 (en) | 2013-09-17 | 2017-07-04 | Yeda Research And Development Co. Ltd. | ERK-derived peptides and uses thereof |
| CN105566485A (zh) * | 2015-12-29 | 2016-05-11 | 米佳 | 一种能靶向抑制epk信号通路的抗肿瘤多肽及其应用 |
| CN110291089B (zh) | 2017-01-17 | 2022-05-27 | 海帕瑞吉尼克斯股份有限公司 | 用于促进肝再生或者减少或预防肝细胞死亡的蛋白激酶抑制剂 |
| IL253642A0 (en) | 2017-07-24 | 2017-09-28 | Seger Rony | Combined treatment for cancer |
| EP3890727A1 (en) * | 2018-12-03 | 2021-10-13 | Yeda Research and Development Co. Ltd | Inhibitors of erk nuclear translocation |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
| US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
| NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
| US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
| US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
| US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
| US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
| US5459036A (en) | 1993-03-19 | 1995-10-17 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Extracellular signal-regulated kinase, sequences, and methods of production and use |
| AU2773695A (en) | 1994-06-13 | 1996-01-05 | Vanderbilt University | Compositions for and methods of enhancing delivery of nucleic acids to cells |
| US6090784A (en) | 1995-12-01 | 2000-07-18 | Yale University | RNA polymerase II peptides and methods of use |
| GB9614871D0 (en) | 1996-07-15 | 1996-09-04 | Smithkline Beecham Plc | Compounds |
| SK151599A3 (en) | 1997-05-14 | 2000-09-12 | Rhone Poulenc Rorer Pharma | Peptide parathyroid hormone analogs |
| BR9815493A (pt) | 1997-07-21 | 2000-10-31 | Pharmacia & Upjohn Ab | Citólise dirigida de células-alvo, agentes e composições que causam citólise, e compostos que podem ser usados para produzir os agentes |
| CA2305370C (en) | 1997-09-26 | 2006-11-28 | Zentaris Gmbh | Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function |
| AU2228299A (en) | 1998-01-14 | 1999-08-02 | Board Of Regents Of The University Of Oklahoma, The | Composition and method for treating metastatic tumors or cancer induced by cellsexpressing sv40 tumor antigen |
| AU5590999A (en) | 1998-09-01 | 2000-03-21 | Trustees Of The University Of Pennsylvania, The | Peptide scaffolds for transfer of molecules into eukaryotic cells |
| US20040091966A1 (en) | 1999-08-30 | 2004-05-13 | Martin Zeidler | Polypeptide regulation by conditional inteins |
| AUPR230500A0 (en) | 2000-12-22 | 2001-01-25 | University Of Newcastle Research Associates Limited, The | A method of modulating map kinase mediated cellular activity and agents useful in same |
| US20040253578A1 (en) | 2001-04-02 | 2004-12-16 | Roberts Radclyffe L. | Dynamic action reference tools |
| US20030083261A1 (en) | 2001-04-30 | 2003-05-01 | Hongtao Yu | Class of 12mer peptides that inhibit the function of the mitotic check point protein Mad2 |
| WO2003070884A2 (en) | 2002-02-20 | 2003-08-28 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF MDR P-GLYCOPROTEIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| ES2662036T3 (es) | 2007-02-28 | 2018-04-05 | Yeda Research And Development Company Limited | Secuencias que se dirigen al núcleo |
| US9695402B2 (en) | 2013-09-17 | 2017-07-04 | Yeda Research And Development Co. Ltd. | ERK-derived peptides and uses thereof |
-
2014
- 2014-09-15 US US15/022,280 patent/US9695402B2/en not_active Expired - Fee Related
- 2014-09-15 EP EP14846055.3A patent/EP3046929B1/en active Active
- 2014-09-15 WO PCT/IL2014/050822 patent/WO2015040609A1/en not_active Ceased
- 2014-09-15 ES ES14846055T patent/ES2717446T3/es active Active
-
2017
- 2017-04-27 US US15/498,493 patent/US10240133B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10240133B2 (en) | 2019-03-26 |
| EP3046929A1 (en) | 2016-07-27 |
| US9695402B2 (en) | 2017-07-04 |
| EP3046929B1 (en) | 2019-01-16 |
| WO2015040609A1 (en) | 2015-03-26 |
| US20170233702A1 (en) | 2017-08-17 |
| EP3046929A4 (en) | 2017-02-08 |
| WO2015040609A8 (en) | 2015-04-23 |
| US20160340655A1 (en) | 2016-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2016000251A1 (es) | Anticuerpos anti-activina y usos de los mismos | |
| CL2016000981A1 (es) | Formulaciones de estrigolactona y sus usos | |
| CL2016002252A1 (es) | Anticuerpos anti-egfrviii y usos de los mismos | |
| DK4056212T3 (da) | Autoinjektor | |
| EP3804591C0 (en) | SKIN CLEANSING DEVICE | |
| HRP20190518T1 (hr) | Tekuća zobena baza | |
| DK2968443T3 (da) | Hepcidinanaloger og anvendelser deraf | |
| EP3020856A4 (en) | Elastic circular knitted fabric | |
| DK2992104T3 (da) | Fremgangsmåde til ekspression | |
| BR112016011147A2 (pt) | autoinjetor | |
| ES1089856Y (es) | Dispositivos de sujecion | |
| DK3065790T3 (da) | Fremgangsmåder til fjernelse af alpha-galactose | |
| DK3068505T3 (da) | Spillesystem og -fremgangsmåde | |
| CL2016001382A1 (es) | Estabilidad de gel mejorada | |
| EP2993194A4 (en) | multiblock | |
| LT3030259T (lt) | Peptidai | |
| IL240701A0 (en) | Kntc2 peptides and vaccines containing the same | |
| EP2978473A4 (en) | AUTOMATIC RETRACTABLE SYRINGE | |
| IL236690B (en) | Ube2t peptides and vaccines containing the same | |
| CL2017002226A1 (es) | Etv2 y usos de los mismos | |
| FI20135815L (fi) | Teline | |
| DE112013007428A5 (de) | Komponententräger | |
| HRP20180520T1 (hr) | Suncobran | |
| DK2821771T3 (da) | Testfremgangsmåde | |
| FR3003470B1 (fr) | Autoinjecteur |